Cybin Inc. Common Stock
HELP
Clasificación en acciones
#11653
Cybin Inc. functions as a biopharmaceutical company currently in its clinical... Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
Precio por acción
$10.30
Última sincronización: 2026-08-11
Capitalización bursátil
$638.32M
Cambio (1 día)
2.88%
Cambio (1 año)
9,119.52%
País
CA
Comercio Cybin Inc. Common Stock (HELP)
Categoría
Healthcare
Ganancias de Cybin Inc. Common Stock (HELP)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Cybin Inc. Common Stock, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Cybin Inc. Common Stock desde 2026 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| Not enough data for the provided dates. | ||
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
